In the midst of International Gaucher Disease Awareness Month, GlobalData has highlighted a 'critical' issue within the Gaucher disease landscape: the significant lack of neuronopathic therapies.
Synlogic is set to increase its manufacturing capacity by more than 50% in preparation for the start of late-stage development of its two lead drug candidates.